Stockscreener 앱 받기
20.27
0.77%
0.17
Vor Biopharma Inc 주식(VOR)의 최신 뉴스
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next - simplywall.st
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Vor Bio grants stock awards to 7 new hires under Nasdaq rule - Stock Titan
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next - Yahoo Finance
3 Reasons Vor Biopharma (VOR) Looks Pricey On Russell Index Inclusion - Sahm
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2500 Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Value Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Value Benchmark Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000E Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2500 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Enterprise value to EBIT forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Vor Biopharma, Inc. Actuals & Estimates (NASDAQ:VOR) - TradingView
Vor Biopharma (VOR) Surges 8% as Shares Test Key Resistance at $16.95Imbalance Zone - dars.gov.et
Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.moomoo - Moomoo
VOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
VOR Q1 2026 Earnings: Severe EPS Miss Highlights Clinical-Stage Biotech ChallengesSegment Revenue Breakdown - dars.gov.et
Vor Biopharma Inc (VOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vor Biopharma Inc (VOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VOR Stock Price, Quote & Chart - ChartMill
Vor Biopharma Inc (VOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vor Biopharma Inc (VOR) Institutional Confidence - TradingKey
Vor Biopharma Inc (VOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vor Biopharma Inc (VOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vor Biopharma Inc (VOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vor Biopharma Q1 2026 Earnings: Deep EPS Miss Amid Ongoing R&D Investment; Stock Edges HigherOne-Time Loss Impact - newsline.com
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
[Form 4] Vor Biopharma Inc. Insider Trading Activity - Stock Titan
Vor Biopharma (VOR) director receives 53,283 stock options at $14.09 strike - Stock Titan
Vor Biopharma (VOR) grants Alexander Cumbo 56,345 stock options - Stock Titan
Vor Biopharma (NASDAQ: VOR) updates and wins approval for 2021 equity plan - Stock Titan
Vor Biopharma (VOR) Stages 3.12% Rally: Potential Breakout Above $15.26 in Sight?Jelly Roll Trade - newsline.com
Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Detheux Michel - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Vor Bio gains boost from telitacicept IgA nephropathy approval - TipRanks
Vor Bio (VOR) drug telitacicept gains China NMPA nods in IgAN and Sjögren’s - Stock Titan
Vor Bio (VOR) Secures Conditional Approval for Telitacicept in C - GuruFocus
Vor Biopharma Inc. and RemeGen Co., Ltd. Receives NMPA Conditional Approval For Telitacicept For The Treatment Of IgA Nephropathy In China - marketscreener.com
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China - Yahoo Finance
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China - GlobeNewswire
Vor Biopharma (VOR) Slips Over 8% as Biotech Sentiment WeighsThematic ETF Flow - newsline.com
Vor Biopharma (VOR) Declines Over 8% as Biotech Sector Faces Headwinds; Key Support Levels TestedMomentum Factor - newsline.com
Vor Biopharma (VOR) Drops Over 8% as Shares Approach Key SupportMax Pain Level - newsline.com
GREAT POINT PARTNERS LLC's Vor Biopharma Inc(VOR) Holding History - GuruFocus
VOR Stock Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar - TipRanks
VOR: Advancing telitacicept in global phase III trials for MG and Sjögren's, targeting major markets - TradingView
Biotech Vor Bio hands 61,050 options, 12,900 RSUs to new staff - Stock Titan
VOR Q1 2026 Earnings: Staggering EPS Miss with Negative Revenue and Sharp Stock DeclineCEO Earnings Statement - newsline.com
VORVor Biopharma Inc Latest SEC Filings - Finviz
Vor Biopharma (VOR) price target decreased by 10.34% to 37.13 - MSN
Vor Biopharma (VOR) Stock Eases Slightly as Shares Hold Near Key Support ZoneSign of Strength - newsline.com
Autoimmune biotech Vor Bio to share update at 2026 Jefferies conference - Stock Titan
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference - marketscreener.com
Vor Biopharma Surges 5.46% as Buyers Defend Key Support Level (VOR)Undervalued Stocks - newsline.com
1.95%
2.70%
자본화:
|
볼륨(24시간):